The key factor determining the efficacy of immunotherapies, including adoptive cell therapy and cancer vaccines, is the generation of cell-mediated immunity, which depends on antigen cross-presentation by APCs and the optimal priming of antigen-specific CD8+ T cells [33, 34]. The gene discussed is CD8A; the disease is cancer.